Lab-Made Alternative Developed for Horseshoe Crab Blood in Medical Testing

Horseshoe Crab Blood in Medicine

For over 40 years, purified horseshoe crab blood has been essential for ensuring the safety of injectable medicines, vaccines, and medical devices. The unique blue blood reacts to dangerous bacteria, making it a critical tool for detecting contamination. This testing is applied to various medical products, including injections, infusions, dialysis equipment, and vaccines.

Impact on Crab Populations

Each year, approximately 200,000 horseshoe crabs are harvested in Massachusetts for biomedical purposes, with nationwide numbers tripling over the last two decades. The Atlantic States Marine Fisheries Commission estimates that about 15% of crabs die as a result of this process. This demand, along with their use as fishing bait, has contributed to a significant decline in horseshoe crab populations along the East Coast, despite their historical resilience.

Ecological Consequences

The decline in horseshoe crab populations has broader ecological implications. Their eggs are a primary food source for various coastal wildlife, including migratory shorebirds, sharks, and turtles. A reduction in the crab population creates a ripple effect throughout the environment, impacting the food chain and overall ecosystem health.

Biotechnology Solution

Scientists have developed a lab-made alternative to horseshoe crab blood for medical testing. This biotechnological solution involves creating the exact same protein found in the crab's blood, eliminating the need to harvest live animals. Eli Lilly and Company, through its senior director Jay Bolden, stated that extensive testing on thousands of samples across hundreds of products confirmed the alternative performs as well as or better than the natural blood.